---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-24-000033"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2024-04-16T23:59:59+00:00"
generated_at: "2026-06-03T22:13:31.647763+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Akebia extends vadadustat supply agreement with STA to 2029

## Summary
- Amendment #2 extends Supply Agreement term to April 2, 2029 (five additional years).
- Agreement covers manufacturing of vadadustat drug substance for commercial purposes.
- Volume-based pricing structure was amended; no financial terms disclosed.
- Original Supply Agreement dated April 2, 2020, previously amended April 15, 2021.
- Contract manufacturer STA Pharmaceutical Hong Kong Limited.

## SEC filing metadata
- accession: 0001517022-24-000033
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2024-04-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000033/0001517022-24-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000033/akba-20241504xwuxiamendment.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-24-000033
- JSON: https://secwatch.observer/filing/0001517022-24-000033.json
- Plain text: https://secwatch.observer/filing/0001517022-24-000033.txt

## Key facts
- Material Agreements
  Akebia Therapeutics, Inc. amended Amendment #2 to the Supply Agreement with STA Pharmaceutical Hong Kong Limited (effective 2024-04-15).
  - Action: amendment
  - Agreement: supply
  - Counterparty: STA Pharmaceutical Hong Kong Limited
  - Effective: 2024-04-15
  source text: (the “Company”) entered into a Supply Agreement with STA Pharmaceutical Hong Kong Limited, a Hong Kong corporation (“STA”), as amended on April 15, 2021 (as amended, the “Supply Agreement”), under which STA manufactures vadadustat drug substance (“Product”) for the Company’s commercial purposes.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000033/0001517022-24-000033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.